• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

James Galeota, Merck

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2008
Volume 0
Issue 0

S

James Galeota

SVP, General Manager, Diabetes and Obesity, Merck

BIGGEST ACCOMPLISHMENT: Establishing Merck's diabetes franchise

ADMIRES: Those that can help others live up to their potential

On stopping the silos:

Commercialization is not about discreet disciplines. At Merck, I have been able to see into different parts of the company and see the value that can be created when all the divisions are synchronized—when you have teams that are aligned around objectives, sharing the same measures of success, holding each other accountable, and working together to solve complex problems.

James Galeota

Articles in this issue
Mary Szela, Abbott
i1-523691-1408670100786.jpg
Mightier Than the Sword
i1-524385-1408669541611.jpg
Keeshia Muhammad, Teva Specialty Pharmaceuticals
i1-524378-1408669555574.jpg
Eric Floyd, Cephalon
i1-524386-1408669540370.jpg
Andrin Oswald, Novartis
i1-524419-1408669476961.jpg
Kimberly Park, Vice President Sales and Marketing, PriCara, Ortho-McNeil Janssen Pharmaceuticals
i1-524398-1408669519362.jpg
Nancy Phelan, Wyeth
i1-524376-1408669559100.jpg
Christoph Westphal, Sirtris
i1-523685-1408670119627.jpg
Tightening the Chain
i1-524387-1408669538146.jpg
Kurt Graves, Vertex
i1-524414-1408669488118.jpg
Wendy Niebler, Shire
i1-523686-1408670117295.jpg
Perfectly Imperfect
i1-523687-1408670114887.jpg
Relaunching Reform
i1-524412-1408669492206.jpg
James Galeota, Merck
i1-524397-1408669520676.jpg
Brett Villagrand, Genentech
Related Videos
Related Content
Nancy Dreyer

What Impact is AI Having on the Collection and Analysis of RWE?

April 25th 2024
Article

AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.

Fierce Females in the Life Science Space

Fierce Females in the Life Science Space

March 29th 2024
Podcast

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

FDA Approves Amneal’s Naloxone Hydrochloride Nasal Spray as an OTC Treatment for Opioid Overdose

FDA Approves Amneal’s Naloxone Hydrochloride Nasal Spray as an OTC Treatment for Opioid Overdose

April 24th 2024
Article

Company aims to provide affordable emergency treatment from overdoses of heroin, fentanyl, and prescription opioids.

Gen-Z Influence on Pharma M&A

Gen-Z Influence on Pharma M&A

March 14th 2024
Podcast

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Image credit: peterschreiber.media | stock.adobe.com

FDA Grants Accelerated Approval to Day One’s Ojemda for Relapsed or Refractory Pediatric Low-Grade Glioma

April 24th 2024
Article

Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.

Amy Brown

Identifying Healthcare Trends from Conversation Data

April 24th 2024
Article

Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.